tiprankstipranks
Merck KGaA (DE:MRK)
XETRA:MRK

Merck KGaA (MRK) Stock Forecast & Price Target

73 Followers
See the Price Targets and Ratings of:

MRK Analyst Ratings

Strong Buy
10Ratings
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Merck
KGaA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

€188.44
▲(23.24% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Merck KGaA in the last 3 months. The average price target is €188.44 with a high forecast of €200.00 and a low forecast of €175.00. The average price target represents a 23.24% change from the last price of €152.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"139":"€139","170":"€170","201":"€201","154.5":"€154.5","185.5":"€185.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":188.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€188.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€175.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[139,154.5,170,185.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.3,173.5076923076923,175.71538461538464,177.92307692307693,180.13076923076923,182.33846153846156,184.54615384615386,186.75384615384615,188.96153846153845,191.16923076923078,193.37692307692308,195.5846153846154,197.7923076923077,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.3,172.61846153846156,173.93692307692308,175.25538461538463,176.57384615384615,177.8923076923077,179.21076923076924,180.52923076923076,181.8476923076923,183.16615384615386,184.48461538461538,185.80307692307693,187.12153846153845,{"y":188.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.3,171.5846153846154,171.86923076923077,172.15384615384616,172.43846153846155,172.72307692307692,173.0076923076923,173.2923076923077,173.5769230769231,173.86153846153846,174.14615384615385,174.43076923076924,174.7153846153846,{"y":175,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":149.352,"date":1688083200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.376,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.257,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.381,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.231,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.228,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.596,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.335,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.164,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.807,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.697,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.3,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€200.00Average Price Target€188.44Lowest Price Target€175.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
€210
Buy
37.34%
Upside
Reiterated
03/20/24
Merck KGaA (MRK:GR) (MKKGY) PT Raised to EUR210 at CitiThe analyst commented: "Expectations of a Life Sciences/Semis recovery are intact (56% of group sales), although the revenue recovery for Merck has been pushed back one quarter to Q3. Elsewhere, Ph III xevinapant data and potential MA (€15-20bn firepower) remain the key focal points; likely Life Sciences focused along with intensifying pipeline in-licensing efforts. We republish our due diligence on key pipeline asset xevinapant along with insights from our KOL call with Prof Harrington. We expect the upcoming interim to pass with Ph III data in Q4 (Citi peak €1.4bn). Our updated forecasts result in unchanged revenue expectations but EBITDA/EPS downgrades reflecting FX, LS/Semi dynamics, and higher pharma RD. Stronger underlying cashflows and revised company WACC/g guidance (7.4%/1.2% versus 8%/2% previously) support our new NPV-derived PT of €210 (bull-bear €269-145). 2024-29E sales/EBITDA/EPS CAGR 7%/11%/12%; Citi up to 15% ahead of consensus."
BMO Capital
€122.32
Buy
-20.00%
Downside
Reiterated
01/09/24
JPM Takeaways: Flipping the Narrative in 2024
HSBC
€170
Buy
11.18%
Upside
Upgraded
12/18/23
HSBC Upgrades Merck KGaA (MRK:GR) (MKGAF) to BuyHSBC analyst Rajesh Kumar upgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Hold to Buy with a price target of EUR170.00.
Credit Suisse
€180
Buy
17.72%
Upside
Reiterated
08/04/23
Exane BNP Paribas Analyst forecast on DE:MRK
Gary Steventon
Not Ranked
Exane BNP Paribas
€150
Hold
-1.90%
Downside
Downgraded
12/12/23
Exane BNP Paribas Downgrades Merck KGaA (MRK:GR) (MKGAF) to NeutralExane BNP Paribas analyst Gary Steventon downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Outperform to Neutral with a price target of EUR150.00.

Best Analysts Covering Merck KGaA

Which Analyst Should I Follow If I Want to Buy DE:MRK and Sell After:
1 Month
Falko FriedrichsDeutsche Numis
Success Rate
13/19 ratings generated profit
68%
Average Return
+2.63%
reiterated a buy rating 2 months ago
Copying Falko Friedrichs's trades and holding each position for 1 Month would result in 68.42% of your transactions generating a profit, with an average return of +2.63% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Peter SpenglerDZ BANK AG
Success Rate
18/26 ratings generated profit
69%
Average Return
+5.81%
reiterated a buy rating 2 months ago
Copying Peter Spengler's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +5.81% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Peter SpenglerDZ BANK AG
Success Rate
19/26 ratings generated profit
73%
Average Return
+15.79%
reiterated a buy rating 2 months ago
Copying Peter Spengler's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +15.79% per trade.
2 Years
Peter SpenglerDZ BANK AG
Success Rate
19/26 ratings generated profit
73%
Average Return
+27.64%
reiterated a buy rating 2 months ago
Copying Peter Spengler's trades and holding each position for 2 Years would result in 73.08% of your transactions generating a profit, with an average return of +27.64% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating
Feb 24
Mar 24
Apr 24
May 24
Jun 24
Strong Buy
0
0
0
0
0
Buy
22
29
23
30
24
Hold
3
0
0
0
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
29
23
30
26
In the current month, MRK has received 24 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is €188.44.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is €2.02 with a range of €2.00 to €2.05. The previous quarter’s EPS was €2.06. MRK beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 67.35% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.
Next quarter’s earnings estimate for MRK is €2.02 with a range of €2.00 to €2.05. The previous quarter’s EPS was €2.06. MRK beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 67.35% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is €5.24B with a range of €5.17B to €5.29B. The previous quarter’s sales results were €5.12B. MRK beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 57.38% of the time in the same period. In the last calendar year MRK has Underperformed its overall industry.
Next quarter’s sales forecast for MRK is €5.24B with a range of €5.17B to €5.29B. The previous quarter’s sales results were €5.12B. MRK beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 57.38% of the time in the same period. In the last calendar year MRK has Underperformed its overall industry.

MRK Stock Forecast FAQ

What is DE:MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck KGaA’s 12-month average price target is €188.44.
    What is DE:MRK’s upside potential, based on the analysts’ average price target?
    Merck KGaA has 23.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Merck KGaA a Buy, Sell or Hold?
          Merck KGaA has a consensus rating of Strong Buy, which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Merck KGaA’s share price target?
            The average share price target for Merck KGaA is €188.44. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €200.00 ,and the lowest forecast is €175.00. The average share price target represents 23.24% Increase from the current price of €152.9.
              What do analysts say about Merck KGaA?
              Merck KGaA’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Merck KGaA?
                To buy shares of DE:MRK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis